Peanut Allergy Market
DelveInsight’s ‘Peanut Allergy – Market Insights, Epidemiology, and Market Forecast – 2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Peanut Allergy in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Peanut Allergy market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Peanut Allergy market size from 2018 to 2030, segmented by seven major markets. The report also covers the current Peanut Allergy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assess the underlying market potential.
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2018–2030
Peanut Allergy: Disease Understanding and Treatment Algorithm
Peanut Allergy Overview
According to the US Food and Drug Administration (FDA) Peanut Allergy is a condition in which the body’s immune system does not recognize peanut protein and mistakenly identifies even tiny amounts of peanut as harmful. Allergic reactions to peanuts are unpredictable in occurrence and how they present, with some individuals experiencing severe reactions from even trace amounts.
The allergy results from an IgE-mediated immediate hypersensitivity reaction to peanuts the consumption (the seeds of Arachis hypogaea). Peanut allergens are designated Ara by the World Health Organization (WHO). Peanut Allergy is the most important food allergy in the US, affecting more than a million people. Reactions range from mild (rashes) to life-threatening (closure of the airway, cardiac dysrhythmias, and coma). About 50 people die of Peanut Allergy in the US each year. A Peanut Allergy occurs when a person’s immune system does not recognize peanut protein and mistakenly overreacts. Both genetic and environmental factors appear to be involved.
The Centers for Disease Control and Prevention (CDC) reports that children with food allergies are more expected to have asthma or other allergic conditions. Nearly 90% of food allergies are caused by these common foods: tree nuts (almonds, walnuts, pecans, cashews, pistachios, etc.), peanuts, milk, eggs, fish, crustacean shellfish, wheat, and soy.
Peanut Allergy symptoms may be mild or may manifest as a severe anaphylactic reaction like urticaria – a red, blotchy, and intensely itchy skin rash commonly referred to as hives. In addition, symptoms include swelling (angioedema) of the face, eyelids, lips, tongue, roof of the mouth, or throat; abdominal cramps, diarrhea, nausea, vomiting; and runny and itchy nose.
Anaphylaxis is the most common reaction in Peanut Allergy patients; it describes a severe and life-threatening allergic reaction. An anaphylactic response is characterized by a swelling of the larynx (voice box) that disrupts the passage of air into the lungs, leading to severe shortness of breath. The swollen larynx also makes it difficult to speak and swallow. In addition, dilated blood vessels may cause a sharp fall of blood pressure, with the skin turning cool and clammy and the sufferer feeling dizzy or even losing consciousness. A weak but rapid pulse may accompany an intense feeling of dread and anxiety.
Concerning the mechanism of Peanut Allergy, at first exposure, the immune system reacts to proteins in the peanuts by producing the antibody immunoglobulin E (IgE), which binds to receptors present on mast cells and basophils. Subsequent exposure to peanuts leads to an inflammatory response governed by these cells, as the peanut protein causes the IgE/receptor complexes to cross-link and activate the release of the inflammatory mediators (e.g., histamine) inside them. Histamine and other inflammatory mediators then trigger the symptoms of an allergic reaction.
Diagnosis of Peanut Allergy involves a detailed evaluation of a patient’s diet history and the severity and duration of their symptoms on exposure to peanuts. Next, a skin test for the allergy may be performed or a blood sample taken to check for IgE. A positive challenge test may be performed in rare cases, where the peanut protein is administered to the patient to examine their allergic reaction.
The US FDA has approved Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp) to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.
Peanut Allergy Diagnosis and Treatment
It covers conventional and current medical therapies and diagnosis available in the Peanut Allergy market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Peanut Allergy market report gives a thorough understanding of Peanut Allergy by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for Peanut Allergy in the US, Europe, and Japan.
Peanut Allergy Epidemiology
The Peanut Allergy epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.
The disease epidemiology covered in the report provides historical and forecasted Peanut Allergy epidemiology segmented as the diagnosed prevalence of Peanut Allergy, gender-specific cases of Peanut Allergy, age-specific cases of Peanut Allergy, and severity-specific cases of Peanut Allergy. The report includes the prevalent scenario of Peanut Allergy in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Country-wise Peanut Allergy Epidemiology
The epidemiology segment also provides the Peanut Allergy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Prevalent population of Peanut Allergy in the 7MM countries was estimated to be 10,578,543 cases in 2020.
Peanut Allergy Drug Chapters
The current market for Peanut Allergy mainly consists of different formulations of immunotherapies, antihistamines, epinephrine, and other therapies such as self-injector.
For patients with mild reactions, such as localized urticaria, oral itch, or mild abdominal pain, treatment may be limited to an oral antihistamine. If the patient has systemic symptoms, the treatment of choice is self-injectable epinephrine administered by intramuscular injection in the lateral thigh. Patients must be educated regarding when to use their self-injector and the proper technique. Epinephrine should likely be administered to any patient with a history of a severe allergic reaction as soon as ingestion of the food allergen is discovered, and the first symptoms appear (and possibly even before symptoms appear).
Antihistamines, known as H1 blockers, are beneficial for treating acute mild reactions (e.g., itching, sneezing, hives, and rashes), although they cannot stop or control a severe reaction. Medications in this class include diphenhydramine and cetirizine.
Palforzia (AR101) is the first FDA-approved oral immunotherapy for Peanut Allergy treatment. It is developed by Aimmune Therapeutics, and it is made up of carefully selected doses of peanut powder taken by mouth. It is designed for children and teens aged 4–17 with existing peanut allergies. The purpose is to desensitize children to peanuts.
Products detail in the report…
Peanut Allergy emerging drugs
CA002 (Camallergy) is a novel and proprietary formulation of whole peanut protein specifically designed to enable the safe and tolerable oral administration of whole peanut protein as oral immunotherapy to treat Peanut Allergy with a formulation and treatment regimen optimized with class-leading efficacy. Camallergy (Cambridge Allergy) is preparing the drug for Phase III trials to treat Peanut Allergy, supporting regulatory approval in the US and Europe. Phase II study demonstrates the safety and efficacy of oral immunotherapy to treat Peanut Allergy, subject to confirmation in Phase III.
Viaskin Peanut/DBV712 (DBV Technologies) is novel epicutaneous immunotherapy applied to the skin via an adhesive patch that is intended to reduce the risk for reactions to accidental peanut ingestion. It is targeted at children 4–11 years of age who suffer from peanut allergies. Viaskin skin patches gradually supply allergenic proteins to Langerhans cells, which are found in the skin. Phase III long-term studies in children ages 4–11, as well as in patients 1–3 years of age, are ongoing. DBV also plans to advance the patches selected for use in the protein transport study (EQUAL) and adhesion and safety study (STAMP) that will be discussed with the FDA. The drug obtained Fast Track and Breakthrough Therapy designation from the US FDA to treat Peanut Allergy in children.
Dupixent/dupilumab (Regeneron/Sanofi) is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins that were invented using Regeneron’s proprietary VelocImmune technology. This technology utilizes a genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. The drug is currently being studied in two Phase II studies for the treatment of Peanut Allergy.
Products detail in the report…
Peanut Allergy Market Outlook
The Peanut Allergy market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Peanut Allergy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Peanut Allergy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.
According to DelveInsight, the Peanut Allergy market in the 7MM is expected to change in the study period 2018–2030.
Peanut avoidance was considered the first line of treatment for anyone at risk of developing a Peanut Allergy. However, the National Institute of Allergy and Infectious Diseases (NIAID) completely overturned their recommendations for children at risk of Peanut Allergy in 2017 after the Learning Early About Peanut Allergy (LEAP) trial presented that children at great risk for having Peanut Allergy were less expected to progress an allergy if they were exposed to peanuts within their first 12 months of life. The updated guidelines outlined when children should be introduced to peanuts based on their allergy risk: high-risk children (with severe eczema, egg allergy, or both) around 4–6 months, moderate-risk children (with mild-to-moderate eczema or other food allergies) around 6 months, and low-risk children (without eczema or food allergies) at their parent’s discretion.
Epinephrine is the first-line medication for the treatment of anaphylaxis. Intramuscular (IM) or intravenous (IV) epinephrine should be administered, although the IM route is preferred, with injection placement in the lateral thigh. IV administration ideally should be done in the inpatient setting with appropriate monitoring. Antihistamines, corticosteroids, and bronchodilators may also be used, but it is essential to realize these medications do not treat anaphylaxis; rather, they are adjunctive therapies for anaphylaxis management. IV fluids should be provided to prevent and treat tissue hypoperfusion.
This section includes a glimpse of the Peanut Allergy market in the 7MM. The market size of Peanut Allergy in the seven major markets was USD 360.8 million in 2020.
The United States: Market Outlook
This section provides Peanut Allergy market size and market size by therapies of Peanut Allergy in the 7MM market.
The United States accounts for the largest market size of Peanut Allergy compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
The growing prevalence of food allergy drives research toward specific allergen immunotherapy (AIT), representing a potential disease-modifying approach. AIT consists of the progressive administration of amounts of the offending allergen to induce food desensitization, creating an increase in reaction threshold with regular exposure to the allergen. It can be performed through oral, sublingual, epicutaneous, and subcutaneous routes. The target is to achieve post desensitization effectiveness: a long-lasting condition allowing patients to introduce food without reactions, even after a period of discontinuation of the offending food.
The promising treatment of Peanut Allergy represented by allergen-specific immunotherapy includes Viaskin Peanut [DBV Technologies] – epicutaneous immunotherapy (EPIT), CA002 [Camallergy] – oral immunotherapy (OIT), and INP20 [InnoUp Farma] – oral immunotherapy (OIT) and ADP101 [Alladapt Immunotherapeutics] – oral immunotherapy (OIT).
EU-5 Countries: Market Outlook
The total Peanut Allergy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.
Japan Market Outlook
The total Peanut Allergy market size and market size by therapies of Peanut Allergy in Japan are also mentioned.
Peanut Allergy Drugs Uptake
This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Peanut Allergy market uptake by drugs, patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
Peanut Allergy Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses Peanut Allergy key players involved in developing targeted therapeutics.
Major players include Nestle Health Sciences, DBV Technologies, Regeneron/Sanofi, Camallergy, and others, whose key products are expected to launch in the US market by 2030.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for Peanut Allergy emerging therapies.
To keep up with current market trends, we take KOLs and SME’s opinions working in the Peanut Allergy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Peanut Allergy market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform a Competitive and Market Intelligence analysis of the Peanut Allergy market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Peanut Allergy, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
- Comprehensive insight has been provided into the Peanut Allergy epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Peanut Allergy is provided, along with the assessment of new therapies which will impact the current treatment landscape.
- A detailed review of the Peanut Allergy market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies by understanding trends shaping and driving the global Peanut Allergy market
- In the coming years, the Peanut Allergy market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Peanut Allergy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Peanut Allergy. The launch of emerging therapies will significantly impact the Peanut Allergy market
- A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Peanut Allergy.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Peanut Allergy Report Insights
- Patient Population
- Therapeutic Approaches
- Peanut Allergy Pipeline Analysis
- Peanut Allergy Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Peanut Allergy Report Key Strengths
- 10-years Forecast
- 7MM Coverage
- Peanut Allergy Epidemiology Segmentation
- Key Competitors
- Highly Analyzed Market
- Drugs Uptake
Peanut Allergy Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- What was the Peanut Allergy Market share (%) distribution in 2018, and how would it look like in 2030?
- What would be the Peanut Allergy total market Size and market Size by therapies across the 7MM during the forecast period (2018–2030)?
- What are the key findings pertaining to the market across 7MM, and which country will have the largest Peanut Allergy market size during the forecast period (2018–2030)?
- At what CAGR, the Peanut Allergy market is expected to grow in the 7MM during the forecast period (2018–2030)?
- What would be the Peanut Allergy market outlook across the 7MM during the forecast period (2018–2030)?
- What would be the Peanut Allergy market growth till 2030, and what will be the resultant market Size in the year 2030?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
- What are the disease risk, burden, and unmet needs of Peanut Allergy?
- What is the historical Peanut Allergy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Peanut Allergy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Peanut Allergy?
- Out of all 7MM countries, which country would have the highest prevalence of Peanut Allergy during the forecast period (2018–2030)?
- At what CAGR is the population expected to grow in the 7MM during the forecast period (2018–2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of Peanut Allergy?
- What are the current treatment guidelines for treating Peanut Allergy in the US, Europe, and Japan?
- What are the Peanut Allergy marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of Peanut Allergy?
- How many therapies are developed by each company for the treatment of Peanut Allergy?
- How many emerging therapies are in the mid-stage and late stages of development to treat Peanut Allergy?
- What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peanut Allergy therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Peanut Allergy and their status?
- What are the key designations that have been granted for the emerging therapies for Peanut Allergy?
- What are the global historical and forecasted markets for Peanut Allergy?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Peanut Allergy market
- To understand the future market competition in the Peanut Allergy market and an Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Peanut Allergy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the Peanut Allergy market.
- To understand the future market competition in the Peanut Allergy market.